加载中
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
收盘时
US$1.26
+US$0.01 · +0.80%
盘后
US$1.26
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
日内区间
当前US$1.26
52周区间
当前US$1.26
盘中时间采用ET。市场数据可能有所延迟。
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
日内区间
当前US$1.26
52周区间
当前US$1.26
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 7699.6万 USD | 1.16亿 USD | 1.42亿 USD | 9840万 USD | 6017万 USD |
| 销售、一般及管理费用 | 2385万 USD | 2609.4万 USD | 2848.3万 USD | 2903.6万 USD | 2338.5万 USD |
| 营业费用 | 1.04亿 USD | 1.42亿 USD | 1.7亿 USD | 1.27亿 USD | 8355.5万 USD |
| 利息收入 | 396.4万 USD | 936.6万 USD | 1064.9万 USD | 427.8万 USD | 91 USD |
| 利息支出 | 160.2万 USD | 172.9万 USD | 156.5万 USD | 23.8万 USD | 1.3万 USD |
| 折旧和摊销 | 70.6万 USD | 87.2万 USD | 83.6万 USD | 34.2万 USD | 5.1万 USD |
| 营业利润 | −1.04亿 USD | −1.42亿 USD | −1.7亿 USD | −1.27亿 USD | −8355.5万 USD |
| 净利润 | −1.02亿 USD | −1.35亿 USD | −1.61亿 USD | −1.23亿 USD | −8346.3万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$17.90
上涨空间 1320.63%价格历史记录不可用
最高：US$38.00平均的：US$17.90最低：US$1.50报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI703.07万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM329.25万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF236.63万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO119.96万0.01%180亿 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO114.73万0.01%139.17亿 USD0.24%US$353.71-0.86%
iShares Micro-Cap ETFIWC38.36万0.03%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM26万0.22%1.17亿 USD0.73%US$15.8484-0.58%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC23.56万0.02%10.49亿 USD0.20%US$86.26-0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
